Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > Drug exposure during pregnancy and «Parent-Child reports» from Switzerland – instructions / recommendations of Swissmedic

https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/mu/drug_exposure_duringpregnancyandparent-childreportsfromswitzerla.pdf.download.pdf/drug_exposure_duringpregnancyandparent-childreportsfromswitzerla.pdf

Philippe Calandra 21 May 2021 All news
  • ← Instruction document of the Spanish Agency for Medicines and Health Products for conducting clinical trials in Spain
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 May 2021 →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • The ANSM publishes its haemovigilance report for 2023
  • User’s booklet – ANSM
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 28-31 October 2024
Copyright © 2018 - Pharmya - Legal terms - Quality Policy